ATE522511T1 - Benzoxazine und verwandte stickstoffhaltige heterobicyclische verbindungen, die sich als mittel zum modulieren des mineralocorticoidrezeptors eignen - Google Patents

Benzoxazine und verwandte stickstoffhaltige heterobicyclische verbindungen, die sich als mittel zum modulieren des mineralocorticoidrezeptors eignen

Info

Publication number
ATE522511T1
ATE522511T1 AT07713915T AT07713915T ATE522511T1 AT E522511 T1 ATE522511 T1 AT E522511T1 AT 07713915 T AT07713915 T AT 07713915T AT 07713915 T AT07713915 T AT 07713915T AT E522511 T1 ATE522511 T1 AT E522511T1
Authority
AT
Austria
Prior art keywords
benzoxazines
modulating
agents
compounds suitable
mineralocorticoid receptor
Prior art date
Application number
AT07713915T
Other languages
English (en)
Inventor
Toru Iijima
Yasuo Yamamoto
Hidenori Akatsuka
Takayuki Kawaguchi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE522511T1 publication Critical patent/ATE522511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT07713915T 2006-02-02 2007-02-01 Benzoxazine und verwandte stickstoffhaltige heterobicyclische verbindungen, die sich als mittel zum modulieren des mineralocorticoidrezeptors eignen ATE522511T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006025403 2006-02-02
JP2006275917 2006-10-10
PCT/JP2007/052165 WO2007089034A1 (en) 2006-02-02 2007-02-01 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents

Publications (1)

Publication Number Publication Date
ATE522511T1 true ATE522511T1 (de) 2011-09-15

Family

ID=38110055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07713915T ATE522511T1 (de) 2006-02-02 2007-02-01 Benzoxazine und verwandte stickstoffhaltige heterobicyclische verbindungen, die sich als mittel zum modulieren des mineralocorticoidrezeptors eignen

Country Status (16)

Country Link
US (2) US7998956B2 (de)
EP (1) EP1984345B9 (de)
KR (1) KR101046548B1 (de)
AR (1) AR059280A1 (de)
AT (1) ATE522511T1 (de)
AU (1) AU2007210424C1 (de)
BR (1) BRPI0707491B8 (de)
CA (1) CA2636985C (de)
DK (1) DK1984345T3 (de)
MX (1) MX285869B (de)
PH (1) PH12008501738B1 (de)
PL (1) PL1984345T3 (de)
PT (1) PT1984345E (de)
RU (1) RU2398769C2 (de)
TW (1) TWI385161B (de)
WO (1) WO2007089034A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679185A1 (en) * 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5314123B2 (ja) * 2008-03-31 2013-10-16 シー アンド シー リサーチ ラボラトリーズ 複素環誘導体
JP2011516494A (ja) * 2008-04-07 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための２Ｈ−ベンゾ［ｂ］［１，４］オキサジン−３（４Ｈ）−オン誘導体
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
ES2682217T3 (es) 2012-08-08 2018-09-19 Mitsubishi Tanabe Pharma Corporation Método para producir un compuesto de 1,4-benzoxazina
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
CN103694137A (zh) * 2013-12-06 2014-04-02 常州工程职业技术学院 一种2-氟-4-硝基苯甲腈的清洁生产方法
EP3160948B1 (de) 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinonamide als mineralocorticoidrezeptormodulatoren
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (de) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Mineralocorticoid-receptor-antagonist zur behandlung von osteoarthritis
TWI603962B (zh) 2016-09-10 2017-11-01 國立清華大學 含硫噁嗪化合物及其合成方法
RU2019112148A (ru) 2016-09-27 2020-10-29 Мицубиси Танабе Фарма Корпорейшн Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2018149754A1 (en) 2017-02-16 2018-08-23 Basf Se Pyridine compounds
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
AR117988A1 (es) 2019-02-05 2021-09-08 Mitsubishi Tanabe Pharma Corp Medicamento para profilaxis o tratamiento para la fibrosis pulmonar
EP4066840A1 (de) 2019-11-26 2022-10-05 Mitsubishi Tanabe Pharma Corporation Prophylaktisches oder therapeutisches mittel für nicht-alkoholische steatohepatitis beim menschen
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (de) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
CN1029479C (zh) 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5420126A (en) * 1989-11-08 1995-05-30 Yamanouchi Pharmaceutical Co., Ltd. 3,4-dihydro-2H-1,4-benzoxazine derivatives and pharmaceutical compositions containing the same
US5696117A (en) 1995-11-07 1997-12-09 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
DE19727117A1 (de) * 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
WO2001057003A1 (en) * 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
PL377770A1 (pl) * 2002-11-08 2006-02-20 F. Hoffmann-La Roche Ag Podstawione benzoksazynony i ich zastosowanie
CN1742007A (zh) * 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
EP1844768A1 (de) * 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatische sulfon-verbindung als aldosteron-rezeptor-modulator

Also Published As

Publication number Publication date
DK1984345T3 (da) 2011-12-12
US20110251185A1 (en) 2011-10-13
BRPI0707491A2 (pt) 2011-05-03
EP1984345B1 (de) 2011-08-31
KR101046548B1 (ko) 2011-07-05
PT1984345E (pt) 2011-09-08
EP1984345A1 (de) 2008-10-29
US20090023716A1 (en) 2009-01-22
TW200800926A (en) 2008-01-01
AR059280A1 (es) 2008-03-19
CA2636985C (en) 2011-08-16
AU2007210424A1 (en) 2007-08-09
AU2007210424C1 (en) 2010-11-18
KR20080083698A (ko) 2008-09-18
WO2007089034A1 (en) 2007-08-09
EP1984345B9 (de) 2012-03-21
BRPI0707491B8 (pt) 2021-05-25
MX285869B (en) 2011-04-19
PL1984345T3 (pl) 2012-01-31
BRPI0707491B1 (pt) 2019-12-10
US8188073B2 (en) 2012-05-29
RU2398769C2 (ru) 2010-09-10
CA2636985A1 (en) 2007-08-09
RU2008135468A (ru) 2010-03-10
TWI385161B (zh) 2013-02-11
US7998956B2 (en) 2011-08-16
PH12008501738B1 (en) 2013-11-29
AU2007210424B2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
ATE522511T1 (de) Benzoxazine und verwandte stickstoffhaltige heterobicyclische verbindungen, die sich als mittel zum modulieren des mineralocorticoidrezeptors eignen
ATE499370T1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
ATE527262T1 (de) Neue tomaymycin derivate enhaltende zytotoxische mittel
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
EP2258731A4 (de) Metallocengestützte katalysatorzusammensetzung und verfahren zur herstellung von polyolefin
BRPI0605921A2 (pt) compostos orgánicos
ATE493411T1 (de) Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
ATE457301T1 (de) Substituierte aryl-acylthioharnstoffe und verwandte verbindungen, virenreplikationshemmer
ATE504587T1 (de) Spiroheterocyclische verbindungen und ihre anwendungen als therapeutische mittel
WO2008073509A3 (en) Compositions and methods for treating a neoplasm
ATE493174T1 (de) Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE458737T1 (de) Peri-kondensierte tricyclische verbindungen verwendbar als antibakterielle mittel
ATE502951T1 (de) Verbindungen und zusammensetzungen als kanalaktivierende protease-hemmer
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
DE602008006045D1 (de) Heterocyclische verbindungen, zusammensetzungen damit und verfahren zu ihrer anwendung
DE602007013081D1 (de) Als anabole mittel für vieh geeignete heterozyklische verbindungen
DE602006019825D1 (de) 1-substituierte-7-(b-d-glycopyranosyloxy)(aza)indolverbindung und pharmazeutikum, das diese enthält
ATE499932T1 (de) Niacin-rezeptoragonisten, zusammensetzungen mit derartigen verbindungen und behandlungsverfahren
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE399777T1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
EP2307407A4 (de) Fxa-inhibitoren mit cyclischem amidoxim oder cyclischem amidazon als p4-untereinheit, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen und derivate davon
DK2064185T3 (da) 1H-quinolin-4-on-forbindelser med affinitet til GABA-receptoren, fremgangsmåder, anvendelser og sammensætninger

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1984345

Country of ref document: EP